of rs1051730 with abstinence in individuals randomized to NRT, and to discover, and then to validate, additional novel biomarker associations with abstinence, will be necessary to develop algorithms for smoking cessation treatment assignment, i.e., personalized medicine [82]. The goal of developing predictive models of treatment response to be implemented into clinical practice will require collaborative efforts from each of the domains of research, policy, industry, and healthcare.
